Search
00
GBAF Logo
trophy
Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

Subscribe to our newsletter

Get the latest news and updates from our team.

Global Banking & Finance Review®

Global Banking & Finance Review® - Subscribe to our newsletter

Company

    GBAF Logo
    • About Us
    • Profile
    • Privacy & Cookie Policy
    • Terms of Use
    • Contact Us
    • Advertising
    • Submit Post
    • Latest News
    • Research Reports
    • Press Release
    • Awards▾
      • About the Awards
      • Awards TimeTable
      • Submit Nominations
      • Testimonials
      • Media Room
      • Award Winners
      • FAQ
    • Magazines▾
      • Global Banking & Finance Review Magazine Issue 79
      • Global Banking & Finance Review Magazine Issue 78
      • Global Banking & Finance Review Magazine Issue 77
      • Global Banking & Finance Review Magazine Issue 76
      • Global Banking & Finance Review Magazine Issue 75
      • Global Banking & Finance Review Magazine Issue 73
      • Global Banking & Finance Review Magazine Issue 71
      • Global Banking & Finance Review Magazine Issue 70
      • Global Banking & Finance Review Magazine Issue 69
      • Global Banking & Finance Review Magazine Issue 66
    Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

    Global Banking & Finance Review® is a leading financial portal and online magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management.
    Copyright © 2010-2026 GBAF Publications Ltd - All Rights Reserved. | Sitemap | Tags | Developed By eCorpIT

    Editorial & Advertiser disclosure

    Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

    Home > Finance > Irish pharma exports to U.S. surge to 10.5 billion euros amid tariff threat
    Finance

    Irish pharma exports to U.S. surge to 10.5 billion euros amid tariff threat

    Published by Global Banking & Finance Review®

    Posted on April 15, 2025

    2 min read

    Last updated: January 24, 2026

    Irish pharma exports to U.S. surge to 10.5 billion euros amid tariff threat - Finance news and analysis from Global Banking & Finance Review
    Why waste money on news and opinion when you can access them for free?

    Take advantage of our newsletter subscription and stay informed on the go!

    Subscribe

    Quick Summary

    Irish pharma exports to the US rose by 450% in February as US drugmakers stockpile amid tariff threats. Trump targets European drug manufacturing.

    Irish Pharma Exports to US Surge Amid Tariff Threats

    DUBLIN (Reuters) -Irish exports of pharmaceutical and medical products to the U.S. surged by more than 450% year-on-year in February, data showed on Tuesday, a second monthly hike that suggested U.S. drugmakers may be stockpiling medicines in advance of potential tariffs.

    The U.S. administration kicked off a probe into imports of pharmaceuticals on Monday as part of a bid to impose tariffs, which President Donald Trump said he expects to add to a raft of duties on other goods and trading partners in the "not-too-distant future".

    Trump has repeatedly singled out the manufacturing of drugs in Europe and particularly Ireland as a problem he intends to tackle through tariffs. More than a dozen of the world's biggest drugmakers have plants in Ireland, where many make medicines or active ingredients for the U.S. market.

    Ireland saw a spike in exports of medicines to the United States in January, when they shot up by 130% to 9.4 billion euros ($10.7 billion). They grew to 10.5 billion euros in February from 1.9 billion in the same month last year, Ireland's Central Statistics Office said.

    Some drugmakers have taken the unusual step of sending more medicines by air to the U.S. amid the tariff threats, two executives and two logistics firms told Reuters last month.

    Ireland's Central Bank attributed a surge in pharma exports to the U.S. from Ireland since last July to the production of highly demanded weight-loss drugs but has said the more recent increases may partly be driven by stockpiling.

    A 34% rise in all goods exports to the U.S. from Ireland last year pushed the U.S. goods trade deficit with the EU member state to a record 50 billion euros.

    ($1 = 0.8817 euros)

    (Reporting by Padraic Halpin and Conor Humphries; Editing by David Holmes)

    Key Takeaways

    • •Irish pharma exports to the US increased by 450% in February.
    • •US drugmakers may be stockpiling due to potential tariffs.
    • •President Trump targets European drug manufacturing with tariffs.
    • •Ireland's January exports to the US rose by 130%.
    • •Ireland's Central Bank cites weight-loss drugs as a key export.

    Frequently Asked Questions about Irish pharma exports to U.S. surge to 10.5 billion euros amid tariff threat

    1What is the main topic?

    The article discusses the surge in Irish pharmaceutical exports to the US amid potential tariff threats by the US administration.

    2Why are US drugmakers stockpiling?

    US drugmakers are stockpiling medicines in anticipation of potential tariffs on European pharmaceuticals.

    3How much did Irish exports increase?

    Irish exports of pharmaceutical products to the US increased by over 450% year-on-year in February.

    More from Finance

    Explore more articles in the Finance category

    Image for French miner Eramet's finance chief steps aside temporarily, days after CEO ouster
    French miner Eramet's finance chief steps aside temporarily, days after CEO ouster
    Image for Ukraine's Zelenskiy calls for faster action on air defence, repairs to grid
    Ukraine's Zelenskiy calls for faster action on air defence, repairs to grid
    Image for Goldman Sachs teams up with Anthropic to automate banking tasks with AI agents, CNBC reports
    Goldman Sachs teams up with Anthropic to automate banking tasks with AI agents, CNBC reports
    Image for Analysis-Hims' $49 weight-loss pill rattles investor case for cash-pay obesity market
    Analysis-Hims' $49 weight-loss pill rattles investor case for cash-pay obesity market
    Image for Analysis-Glencore to focus on short-term disposals as Rio deal remains elusive
    Analysis-Glencore to focus on short-term disposals as Rio deal remains elusive
    Image for Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut
    Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut
    Image for Big Tech's quarter in four charts: AI splurge and cloud growth
    Big Tech's quarter in four charts: AI splurge and cloud growth
    Image for EU hikes tariffs on Chinese ceramics to 79% to counter dumping 
    EU hikes tariffs on Chinese ceramics to 79% to counter dumping 
    Image for AI trade splinters as investors get more selective
    AI trade splinters as investors get more selective
    Image for EU extends tariff suspension on $109.8 billion of US imports for six months
    EU extends tariff suspension on $109.8 billion of US imports for six months
    Image for Dog food maker Ollie acquired by Spain’s Agrolimen
    Dog food maker Ollie acquired by Spain’s Agrolimen
    Image for Salzgitter to take over HKM steel joint venture, end clash with Thyssenkrupp
    Salzgitter to take over HKM steel joint venture, end clash with Thyssenkrupp
    View All Finance Posts
    Previous Finance PostU.S. policy on stablecoins more dangerous than tariffs, Italian minister says
    Next Finance PostItaly's defence minister says decision on Musk's Starlink should be technical